Advertisement

Timothy J. Whelan, MD: When Can Radiotherapy Be Avoided After Breast-Conserving Surgery?
0 seconds of 0 secondsVolume 90%
Press shift question mark to access a list of keyboard shortcuts
Keyboard Shortcuts
Play/PauseSPACE
Increase Volume
Decrease Volume
Seek Forward
Seek Backward
Captions On/Offc
Fullscreen/Exit Fullscreenf
Mute/Unmutem
Decrease Caption Size-
Increase Caption Size+ or =
Seek %0-9
00:00
00:00
00:00
 

Timothy J. Whelan, MD: When Can Radiotherapy Be Avoided After Breast-Conserving Surgery?

2022 ASCO Annual Meeting

Advertisement

Timothy J. Whelan, MD, of McMaster University and Hamilton Health Sciences, discusses findings from the LUMINA study, which found that women aged 55 or older who had grade 1–2 T1N0 luminal A breast cancer following breast-conserving surgery and were treated with endocrine therapy alone had very low rates of local tumor recurrence at 5 years. These patients, the research suggests, may be able to forgo radiotherapy (Abstract LBA501).



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
Women with breast cancer, early stage breast cancer, are primarily treated with lumpectomy, often endocrine therapy and radiation. And for many years now we've realized that the risk of local recurrence after lumpectomy has been steadily decreasing, and this has been attributed to smaller screen detected cancers, better surgical therapies and better systemic therapy. And radiation itself is associated with significant side effects, both early, such as fatigue and skin irritation, and late side effects such as breast distortion, which can affect cosmesis and quality of life. And rare life threatening side effects such as cardiac disease and second cancers. The question is arisen, can we avoid radiotherapy in women who are already going to have lumpectomy and endocrine therapy? We've done a number of studies which have evaluated clinical pathological factors alone, but haven't been able to identify a very low risk group of patients after lumpectomy and endocrine therapy alone. But over the last two decades, we realized a better understanding of the molecular biology of breast cancer and have identified four major intrinsic subtypes of breast cancer. Luminal A being the most common subtype and also the lowest risk subtype. The objective of our study was to determine women with clinical pathological factors, low risk and the Luminal A subtype who were treated with lumpectomy and endocrine therapy alone. Could they avoid radiotherapy? The Luminal was a prospective cohort study where we followed 500 women who had low clinical risk factors and Luminal A subtype determined by ER, PR, HER2 and a low Ki-67, less than 13.25%, which was measured centrally in three labs using the international working group methods. And we found over five years that women had a very low rate of local recurrence, only 2.3% with the upper border of the 90% confidence interval being 3.8%, which was well below the 5% limit that we had set for ourselves. We believe that this rate is very low and constitutes that we could omit radiotherapy in this low risk subtype. Should point out that the risk of contralateral breast cancer in this group of women was only 1.8%. Very similar to the risk of local recurrence and the risk of any recurrence was only 2.7%. Again, a low risk group of patients. Based on these results in women who meet the clinical criteria for the study, and I'll mention again, they were women less than or equal to 50 or greater than or equal to 55 years of age who had a T1 N0 cancer, grades 1 and 2, and the luminal A subtype as we determined who were treated with endocrine therapy, they can avoid radiotherapy. Now, although Luminal A is a common subtype, we estimate that this group of women probably constitutes about 10 to 15% of all women with breast cancer. Given that the risk of invasive breast cancer is about 300,000 annually per year in North America, we estimate that this would relate to about 30 to 40,000 women per year.

Related Videos

Lung Cancer
Immunotherapy

Gilberto de Lima Lopes, Jr, MD, MBA, and Karen L. Reckamp, MD, on NSCLC: Overall Survival Results With Ramucirumab Plus Pembrolizumab vs Standard of Care

Gilberto de Lima Lopes, Jr, MD, MBA, of the Sylvester Comprehensive Cancer Center at the University of Miami, and Karen L. Reckamp, MD, of Cedars-Sinai Medical Center, discuss phase II findings from substudy S1800A of the Lung-MAP protocol. The data showed that ramucirumab and pembrolizumab improved overall survival compared with the standard of care for patients with advanced non–small cell lung cancer who were previously treated with immunotherapy and platinum-based chemotherapy (Abstract 9004).

 

Breast Cancer
Immunotherapy

Erika Hamilton, MD, on Metastatic Breast Cancer: Safety Follow-up Data on T-DXd vs T-DM1

Erika Hamilton, MD, of Sarah Cannon Research Institute at Tennessee Oncology, discusses phase III data from the DESTINY-Breast03 study, which reinforced the consistent safety profile of fam-trastuzumab deruxtecan-nxki (T-DXd) vs ado-trastuzumab emtansine (T-DM1) in patients with HER2-positive unresectable and/or metastatic breast cancer. The findings also support T-DXd’s risk benefit over that of T-DM1 (Abstract 1000).

Prostate Cancer
Genomics/Genetics

Neal D. Shore, MD, on Germline Genetic Testing and Its Impact on Prostate Cancer Clinical Decision-Making

Neal D. Shore, MD, of the Carolina Urologic Research Center, discusses his study findings, showing that germline genetic testing influenced care for patients with prostate cancer. Men whose genetic test was positive for a pathogenic germline variant received more recommendations for changes to follow-up and treatment, and for testing and counseling of relatives, than did patients with negative or uncertain test results (Abstract 10500).

 

Bladder Cancer

Karim Chamie, MD, on Bladder Cancer: Final Results on N-803 and Bacillus Calmette-Guérin

Karim Chamie, MD, of the University of California, Los Angeles, discusses final clinical results on combining the superagonist N-803 with bacillus Calmette-Guérin (BCG) in patients whose carcinoma in situ and high-grade non–muscle-invasive bladder cancers are unresponsive to BCG alone. Of note, cystectomy was avoided in more than 90% of patients with 2 years of follow-up (Abstract 4508).

Breast Cancer
Immunotherapy

Ann H. Partridge, MD, MPH, and Ian E. Krop, MD, PhD, on Metastatic Breast Cancer: New Early Data on Patritumab Deruxtecan

Ann H. Partridge, MD, MPH, Dana-Farber Cancer Institute, and Ian E. Krop, MD, PhD, of Yale Cancer Center, discuss phase I/II findings on patritumab deruxtecan, a HER3-directed antibody-drug conjugate, in patients with HER3-expressing metastatic breast cancer. A pooled analysis showed antitumor activity in women with HR-positive/HER2-negative and HER2-positive advanced disease, as well as triple-negative breast cancer (Abstract 1002).

Advertisement

Advertisement




Advertisement